Marketing-authorisation holder · Canada
Boehringer Ingelheim (Canada) Ltd Ltee
109 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
109 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 109
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ATROVENT HFA20 mcg / act · Aerosol (Metered-Dose) | Ipratropium bromide | Canada | Marketed | 2004 |
| COMBIVENT RESPIMAT20 mcg / act + 100 mcg / act · Solution | Ipratropium bromide, Salbutamol | Canada | Marketed | 2014 |
| GIOTRIF40 mg · Tablet | Afatinib | Canada | Marketed | 2014 |
| GIOTRIF20 mg · Tablet | Afatinib | Canada | Marketed | 2014 |
| GIOTRIF30 mg · Tablet | Afatinib | Canada | Marketed | 2014 |
| HERNEXEOS60 mg · Tablet | Zongertinib | Canada | Authorised | |
| INSPIOLTO RESPIMAT2.5 mcg / act + 2.5 mcg / act · Solution | Olodaterol, Tiotropium bromide | Canada | Marketed | 2015 |
| JARDIANCE25 mg · Tablet | Empagliflozin | Canada | Marketed | 2015 |
| JARDIANCE10 mg · Tablet | Empagliflozin | Canada | Marketed | 2015 |
| JENTADUETO2.5 mg + 1000 mg · Tablet | Linagliptin, Metformin | Canada | Marketed | 2013 |
| JENTADUETO2.5 mg + 500 mg · Tablet | Linagliptin, Metformin | Canada | Marketed | 2013 |
| JENTADUETO2.5 mg + 850 mg · Tablet | Linagliptin, Metformin | Canada | Marketed | 2013 |
| MICARDIS 40MG TAB40 mg · Tablet | Telmisartan | Canada | Marketed | 1999 |
| MICARDIS 80MG TAB80 mg · Tablet | Telmisartan | Canada | Marketed | 1999 |
| MICARDIS PLUS12.5 mg + 80 mg · Tablet | Hydrochlorothiazide, Telmisartan | Canada | Marketed | 2001 |
| MICARDIS PLUS25 mg + 80 mg · Tablet | Hydrochlorothiazide, Telmisartan | Canada | Marketed | 2008 |
| MIRAPEX0.25 mg · Tablet | Pramipexole | Canada | Marketed | 1998 |
| MIRAPEX0.125 mg · Tablet | Pramipexole | Canada | Marketed | 2008 |
| OFEV100 mg · Capsule | Nintedanib | Canada | Marketed | 2015 |
| OFEV150 mg · Capsule | Nintedanib | Canada | Marketed | 2015 |
| PRADAXA110 mg · Capsule | Dabigatran etexilate | Canada | Marketed | 2008 |
| PRADAXA150 mg · Capsule | Dabigatran etexilate | Canada | Marketed | 2010 |
| PRAXBIND50 mg / ml · Solution | Idarucizumab | Canada | Marketed | 2016 |
| SPIRIVA18 mcg · Capsule | Tiotropium bromide | Canada | Marketed | 2002 |
| SPIRIVA RESPIMAT2.5 mcg / act · Solution | Tiotropium bromide | Canada | Marketed | 2014 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 109 | 36 | 73 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.